2010 Rayno Life Science Portfolio: Update Biopharma
2010 Price Original P Price % Ret 7/2/10 Recomm 12/1/10 Alexion ALXN 50.45 2/2/09 35 76.24 117 Ardea Biosci RDEA 19.5 2/2/09 12 22.26 85 Amgen AMGN 51.7 2/2/09 55 53.52 -5 Biogen BIIB 49.42 2/2/09 49 65.37 33 Cephalon CEPH 55.95 2/2/09 77 64.26 -16.5 Cubist CBST 20.7 2/2/09 22 20.98 -4.5...
Rayno Life Science Portfolio Update: Biotechs beat the Market
As of the end of Q3, 2010 has been a very good year for biotechnology stocks beating both the S&P (up 2.9% YTD) and the NASDAQ (up 4.9% YTD). However the QQQQ was up 7.75% YTD. The NYSE Arca Biotech Index is up 23.5% YTD and the First Trust Amex Biotech ETF (FBT) is up 22% YTD. Other drug...
Stealth Stock Rally Catches Bears off Guard:Don’t Fight the Tape
Biotech stocks rallied with the general market today with many large caps beating the QQQQ which is up about 1.85% as of midday trading. Within the Rayno Life Science Portfolio today's winners were: Large Caps-Biogen (BIIB) up 2.4%,Cephalon(CEPH) up 2.25%, Gilead (GILD) up 2.25%; Small and Mid...
Rodman&Renshaw Part 2:Rosetta Genomics(ROSG)and Response Genetics(RGDX)
Within the "diagnostics and tools" track at the Rodman and Renshaw Conference here are two interesting genomics companies that presented. Rosetta Genomics Ltd. (ROSG, $1.25) ,Market Cap $21M, Sh.Out. 16.5M Rosetta is an Israeli Company focused in development of microRNA-based diagnostics...
Rodman&Renshaw Notes Part 2: Sequenom (SQNM)
Sequenom (SQNM) $7, Market Cap $529M, 76M Sh. Outstanding Sequenom presented a financial update and their plans for their T21 trisomy 21 noninvasive pre-natal test for fetal gene and chromosomal abnormalities. The Company plans to launch a CLIA LDT (lab developed test) by Q4 2011 and submit a...